Specifically, emerging areas of cetuximab resistance research in head and neck cancer involve EFNB2 (Chaudhary et al., 2023a), NRG1 (Iida et al., 2022), TRIP13-pY56 (Banerjee et al., 2022), and mathematical resistance prediction models (Cárdenas et al., 2022). The gene discussed is TRIP13; the disease is head and neck cancer.